Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled β2-adrenoceptor agonists

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 382, Issue 3, 2010, Pages 255-263

  Rosethorne, Elizabeth M ^a   Turner, Robert J ^a   Fairhurst, Robin A ^b   Charlton, Steven J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

2 adrenoceptor; cAMP; Efficacy; Indacaterol; Onset

Indexed keywords

3 [4 [[6 [[2 HYDROXY 2 [4 HYDROXY 3 (HYDROXYMETHYL)PHENYL]ETHYL]AMINO]HEXYL]OXY]BUTYL]BENZENESULFONAMIDE; ADRENALIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARMOTEROL; CYCLIC AMP; FORMOTEROL; INDACATEROL; ISOPRENALINE; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

ARTICLE; BRONCHODILATATION; BRONCHUS MUSCLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; LIPOPHILICITY; SMOOTH MUSCLE FIBER;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHI; BRONCHODILATOR AGENTS; CELL LINE; CELLS, CULTURED; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY; MYOCYTES, SMOOTH MUSCLE; RECEPTORS, ADRENERGIC, BETA-2; TIME FACTORS;

EID: 77957585604     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-010-0533-6     Document Type: Article

References (22)

1. GP Anderson A Linden KF Rabe 1994 Why are long-acting β-adrenoceptor agonists long-acting? Eur Respir J 7 569 578 10.1183/09031936.94.07030569 1:CAS:528:DyaK2cXkvFyrurc%3D 7912202
2. C Battram SJ Charlton B Cuenoud MR Dowling RA Fairhurst D Farr JR Fozard JR Leighton-Davies CA Lewis L McEvoy RJ Turner A Trifilieff 2006 In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5, 6-diethyl-indan-2- ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action J Pharmacol Exp Ther 317 762 770 10.1124/jpet.105.098251 1:CAS:528:DC%2BD28XktFamu70%3D 16434564
3. 2-adrenoceptor agonist J Med Chem 53 3675 3684 10.1021/jm100068m 1:CAS:528:DC%2BC3cXkvFaqtbs%3D 20402514
4. LJ Brookman LJ Knowles M Barbier B Elharrar R Fuhr S Pascoe 2007 Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma Curr Med Res Opin 23 3113 3122 10.1185/030079907X242863 1:CAS:528:DC%2BD1cXhslOksbk%3D 17999782
5. M Cazzola MG Matera 2009 Emerging inhaled bronchodilators: an update Eur Respir J 34 757 769 10.1183/09031936.00013109 1:CAS:528:DC%2BD1MXht1Whsb7L 19720811
6. Dahl R, Greefhorst LAPM, Nowak D, Nonikov V, Byrne AM, Thomson MH et al (2001) Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Resp Crit Care 164:778-784
7. 2-adrenergic receptor signaling and function in airway smooth muscle FASEB 22 2134 2141 10.1096/fj.07-102459 1:CAS:528:DC%2BD1cXotlantb4%3D (Pubitemid 351948632)
8. 2-adrenergic receptor J Biol Chem 283 5669 5676 10.1074/jbc.M708118200 1:CAS:528:DC%2BD1cXit1OmtLo%3D 18086673
9. 2-adrenergic receptor lacking the cyclic AMP-dependent protein kinase consensus sites fully activates extracellular signal-regulated kinase 1/2 in human embryonic kidney 293 cells: lack of evidence for Gs/Gi switching Mol Pharmacol 62 1094 1102 10.1124/mol.62.5.1094 1:CAS:528:DC%2BD38XosVKju7o%3D 12391272 (Pubitemid 35222500)
10. 2-selectivity of Ta-2005, a newly developed bronchodilating agent, in isolated guinea-pig tissues Jpn J Pharmacol 57 175 185 10.1254/jjp.57.175 1:CAS:528:DyaK38Xlt1Y%3D 1687479
11. C Krasel JP Vilardaga M Bunemann MJ Lohse 2004 Kinetics of G-protein-coupled receptor signalling and desensitization Biochem Soc Tran 32 1029 1031 10.1042/BST0321029 1:CAS:528:DC%2BD2cXptVSlur0%3D (Pubitemid 39655535)
12. D Lombardi B Cuenoud SD Kramer 2009 Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 38 533 547 10.1016/j.ejps.2009.10.001 1:CAS:528: DC%2BD1MXhsVKgsL3J 19819331
13. 2-agonist, on isolated human bronchi Eur Respir J 29 575 581 10.1183/09031936.00032806 1:CAS:528: DC%2BD2sXjs1yksbo%3D 17135231 (Pubitemid 46372108)
14. M Palmqvist G Persson L Lazer J Rosenborg P Larsson J Lotvall 1997 Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency Eur Respir J 10 2484 2489 10.1183/09031936.97.10112489 1:CAS:528:DyaK1cXhtFWlsw%3D%3D 9426083 (Pubitemid 28048620)
15. 2 adrenergic receptor agonists incorporating arylsulfonamide groups J Med Chem 52 2280 2288 10.1021/jm801016j 1:CAS:528:DC%2BD1MXjs1GlsL8%3D 19317397
16. S Rennard T Bantje S Centanni P Chanez A Chuchalin A D'Urzo O Kornmann S Perry D Jack R Owen M Higgins 2008 A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison Respir Med 102 1033 1044 10.1016/j.rmed.2008.02.001 18479895
17. DG Rhodes R Newton R Butler L Herbette 1992 Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers Mol Pharmacol 4 596 602
18. 2 adrenoceptor is governed by agonist efficacy. pA2online 6(1):002P
19. MR Sears J Lotvall 2005 Past, present and future-β2-adrenoceptor agonists in asthma management Respir Med 99 152 170 10.1016/j.rmed.2004.07.003 15715182 (Pubitemid 40104270)
20. RK Sharma PK Jeffery 1990 Airway beta-adrenoceptor number in cystic fibrosis and asthma Clin Sci (Lond) 78 409 417 1:STN:280:DyaK3c3lsFSqug%3D%3D
21. 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices J Pharmacol Exp Ther 324 270 275 10.1124/jpet.107.129296 1:CAS:528:DC%2BD1cXhsF2gsQ%3D%3D 17916760 (Pubitemid 350294169)
22. JR Traynor MJ Clark AE Remmers 2002 Relationship between rate and extent of G protein activation: comparison between full and partial opioid agonists J Pharmacol Exp Ther 300 157 161 10.1124/jpet.300.1.157 1:CAS:528: DC%2BD38Xht1WntQ%3D%3D 11752111 (Pubitemid 34028522)